79619-25-3

Usage

Type of compound

Ketone derivative

Backbone

Pentanone

Substituent

4-Trifluoromethoxyphenyl

Application

Organic synthesis and pharmaceutical research

Use

Building block for preparation of biologically active molecules

Potential properties

Antifungal and antibacterial

Significance in drug development

Candidate for further study

Trifluoromethoxy group

Enhances lipophilicity and metabolic stability

Importance in drug discovery and medicinal chemistry

Valuable tool

Upstream product

• 120-92-3 cyclopentanone 
• 36823-88-8 4-(trifluoromethoxy)benzoyl chloride 
• 57330-50-4 4-(dimethylaminocarbonyl)trifluoromethoxybenzene 
• 693-04-9 butyl magnesium bromide 
• 109-65-9 1-bromo-butane 
• 332-25-2 4-(trifluoromethoxy)benzonitrile 

Downstream Products

• 187737-37-7 propene 
• 85013-98-5 1-[4-(trifluoromethoxy)phenyl]ethan-1-one 

Relevant academic research and scientific papers

Suzuki-Miyaura coupling of simple ketones via activation of unstrained carbon-carbon bonds

Here, we describe that simple ketones can be efficiently employed as electrophiles in Suzuki-Miyaura coupling reactions via catalytic activation of unstrained C-C bonds. A range of common ketones, such as cyclopentanones, acetophenones, acetone and 1-indanones, could be directly coupled with various arylboronates in high site-selectivity, which offers a distinct entry to more functionalized aromatic ketones. Preliminary mechanistic study suggests that the ketone α-C-C bond was cleaved via oxidative addition.

Benzamide derivatives, preparation method of benzamide derivatives and application of benzamide derivatives in medicines

The invention relates to benzamide derivatives, a preparation method of benzamide derivatives and an application of the benzamide derivatives in medicines. Specifically, the invention relates to a benzamide derivative shown as a general formula (I), a preparation method of the benzamide derivative, medicinal salts thereof, as well as an application of the benzamide derivatives as therapeutic agents, particularly as glucagon receptor antagonists. The definition of each substituent group in the general formula (I) is the same as the definition in the specification.